Isomorphic Labs will use the proceeds to expand its drug design engine, IsoDDE, and advance its pipeline of potential medicines.

UK—Isomorphic Labs has raised US$5 billion in a Series C financing round to scale its artificial intelligence (AI) drug discovery platform and advance its therapeutic candidates towards clinical trials.
Sequoia Capital and Greenoaks co-led the oversubscribed funding round, which also attracted Andreessen Horowitz (a16z) and other new investors.
Alphabet maintained its financial backing, alongside existing investors CapitalG, GV, MGX, Temasek, Thrive Capital and the UK Sovereign AI Fund.
Funding to accelerate AI-driven drug development
Isomorphic Labs will use the proceeds to expand its drug design engine, IsoDDE, and advance its pipeline of potential medicines.
The platform combines foundational simulation models that operate across different therapeutic areas and drug modalities to identify and optimise molecules with drug-like properties.
The company has reported positive preclinical findings from collaborative projects and internal research programmes targeting immunology and oncology.
It is now preparing selected candidates for initial clinical evaluation.
Founder and CEO Demis Hassabis said the company was established on the premise that AI could help researchers understand and model biology at the molecular level, accelerating the discovery of new medicines.
He explained that the latest funding would support the development of foundational biology models, improve the company’s understanding of disease mechanisms and advance its first therapeutic programmes towards clinical trials.
The investment will also support the development of translational research and clinical infrastructure required to move drug candidates from preclinical research into human testing.
In addition, Isomorphic Labs plans to establish a network of research partners to strengthen its understanding of disease biology.
It will also expand its global infrastructure for bioengineering and computational biology operations.
Investment strengthens UK life sciences sector
The financing has attracted attention from the UK’s life sciences industry, given the growing role of AI in pharmaceutical research and development.
Chris Molloy, CEO of the BioIndustry Association (BIA), told Pharmaceutical Technology that the £3.8 billion (US$5 billion) investment represents a significant milestone for UK-founded companies and global life sciences venture capital funding.
He described the funding as a vote of confidence in the UK’s life sciences industry and its emerging technology-driven biotechnology sector.
He also highlighted the potential of combining AI with drug discovery to address diseases that lack effective treatments.
Molloy noted that investment in scientifically driven companies could help them expand their operations, commercialise research and develop medicines for global markets.
The latest financing follows Isomorphic Labs’ US$600 million funding round in March 2025, its first external investment since its establishment.
The company continues to develop AI-based approaches to drug discovery, with its latest funding directed towards expanding its technology, research capabilities and clinical development activities.
Be the first to leave a comment